Literature DB >> 17078916

Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004.

A C Lékané Likeufack1, R Brun, A Fomena, P Truc.   

Abstract

The situation of human African trypanosomiasis remains serious with one of the main threats being the increasing number of relapses or treatment failures after melarsoprol treatment. In order to investigate and to compare drug sensitivities of trypanosomes isolated at different time periods and in different locations, two sets of Trypanosoma brucei gambiense strains were used. One set was isolated in the time period 1960-1981 and the other one in 1995-2004 from different locations of West and Central Africa. These isolates were not selected based on the treatment outcome but on availability. The drug sensitivity profile for all available drugs in use and the diamidine compound DB75 was established. IC(50) values were not significantly different between the "old" and "new" stocks. No indications for emerging drug resistance to any drug could be observed. The results indicate a relative stability of in vitro sensitivity of T. b. gambiense to trypanocidal drugs in space (West and Central Africa) and time (1960-2004).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078916     DOI: 10.1016/j.actatropica.2006.09.003

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  12 in total

1.  Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.

Authors:  Antoaneta Y Sokolova; Susan Wyllie; Stephen Patterson; Sandra L Oza; Kevin D Read; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Authors:  Tanja Wenzler; Sihyung Yang; Olivier Braissant; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

4.  Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes.

Authors:  David F Bruhn; Susan Wyllie; Adaris Rodríguez-Cortés; Angela K Carrillo; R Kiplin Guy; Alan H Fairlamb; Richard E Lee
Journal:  J Antimicrob Chemother       Date:  2015-12-18       Impact factor: 5.790

5.  Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.

Authors:  Patient Pati Pyana; Ipos Ngay Lukusa; Dieudonné Mumba Ngoyi; Nick Van Reet; Marcel Kaiser; Stomy Karhemere Bin Shamamba; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2011-04-19

6.  Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Harry Pieter De Koning; Sarah Ann Thomas
Journal:  J Pharmacol Exp Ther       Date:  2009-03-04       Impact factor: 4.030

7.  Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.

Authors:  Deuan C Jones; Irene Hallyburton; Laste Stojanovski; Kevin D Read; Julie A Frearson; Alan H Fairlamb
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

Review 8.  Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.

Authors:  Stephen Wring; Eric Gaukel; Bakela Nare; Robert Jacobs; Beth Beaudet; Tana Bowling; Luke Mercer; Cyrus Bacchi; Nigel Yarlett; Ryan Randolph; Robin Parham; Cindy Rewerts; Jacob Platner; Robert Don
Journal:  Parasitology       Date:  2013-09-05       Impact factor: 3.234

9.  The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Barbara Bradley; Sarah Ann Thomas
Journal:  J Neurochem       Date:  2008-09-24       Impact factor: 5.372

10.  Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.

Authors:  Fabrice E Graf; Philipp Ludin; Tanja Wenzler; Marcel Kaiser; Reto Brun; Patient Pati Pyana; Philippe Büscher; Harry P de Koning; David Horn; Pascal Mäser
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.